MENU
+Compare
JAZZ
Stock ticker: NASDAQ
AS OF
Oct 13 closing price
Price
$135.14
Change
-$0.29 (-0.21%)
Capitalization
8.2B

JAZZ Jazz Pharmaceuticals plc Forecast, Technical & Fundamental Analysis

Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology... Show more

JAZZ
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for JAZZ with price predictions
Oct 13, 2025

Momentum Indicator for JAZZ turns positive, indicating new upward trend

JAZZ saw its Momentum Indicator move above the 0 level on September 26, 2025. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 94 similar instances where the indicator turned positive. In of the 94 cases, the stock moved higher in the following days. The odds of a move higher are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where JAZZ advanced for three days, in of 290 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 190 cases where JAZZ Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for JAZZ moved out of overbought territory on October 06, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 22 similar instances where the indicator moved out of overbought territory. In of the 22 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 69 cases where JAZZ's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for JAZZ turned negative on October 13, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where JAZZ declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

JAZZ broke above its upper Bollinger Band on October 01, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. JAZZ’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to slightly better than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.212) is normal, around the industry mean (24.216). P/E Ratio (15.380) is within average values for comparable stocks, (54.710). JAZZ's Projected Growth (PEG Ratio) (5.957) is slightly higher than the industry average of (2.181). Dividend Yield (0.000) settles around the average of (0.044) among similar stocks. P/S Ratio (2.040) is also within normal values, averaging (342.828).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. JAZZ’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
JAZZ
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

JAZZ is expected to report earnings to fall 171.88% to $5.93 per share on November 05

Jazz Pharmaceuticals plc JAZZ Stock Earnings Reports
Q3'25
Est.
$5.93
Q2'25
Missed
by $0.63
Q1'25
Missed
by $3.13
Q4'24
Beat
by $0.81
Q3'24
Beat
by $1.11
The last earnings report on August 05 showed earnings per share of -825 cents, missing the estimate of -761 cents. With 369.29K shares outstanding, the current market capitalization sits at 8.20B.
A.I. Advisor
published General Information

General Information

a specialty biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Pharmaceuticals Other
Address
Waterloo Road
Phone
+353 16347800
Employees
2800
Web
https://www.jazzpharmaceuticals.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
WSHFX66.401.01
+1.54%
American Funds Washington Mutual F1
RPFRX40.090.34
+0.86%
Davis Real Estate A
FAOIX37.93N/A
N/A
Fidelity Advisor Overseas I
GCITX17.11N/A
N/A
Goldman Sachs Intl Eq Insghts Inv
PSSJX23.41N/A
N/A
Principal SmallCap S&P 600 Index J

JAZZ and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, JAZZ has been loosely correlated with BMRN. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if JAZZ jumps, then BMRN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To JAZZ
1D Price
Change %
JAZZ100%
-0.21%
BMRN - JAZZ
45%
Loosely correlated
+0.25%
AMLX - JAZZ
43%
Loosely correlated
-0.98%
TECH - JAZZ
43%
Loosely correlated
+1.69%
FTRE - JAZZ
41%
Loosely correlated
+1.50%
ROIV - JAZZ
40%
Loosely correlated
+1.06%
More